Prestige BioPharma Limited
KSE:950210.KS
15930 (KRW) • At close November 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Operating Activities: | |||||||
| Net Income
| -55,098.01 | -2,858.766 | -211,450.137 | -7,390.936 | -14,996.866 | -1,447.487 | -2,228.32 |
| Depreciation & Amortization
| 16,267.13 | 11,649.79 | 3,866.586 | 1,667.282 | 1,184.944 | 573.679 | 240.237 |
| Deferred Income Tax
| 0 | -39,460.844 | 181,679.994 | -15,026.336 | 0 | 0 | 0 |
| Stock Based Compensation
| 52.414 | 1,943.154 | 3,773.82 | 2,954.573 | 0 | 0 | 0 |
| Change In Working Capital
| 11,052.726 | -18,722.518 | -19,044.278 | 2,072.726 | -3,024.342 | 7,557.386 | 1,954.876 |
| Accounts Receivables
| 5,101.588 | -6,416.934 | 179.204 | 1,246.514 | 9,594.746 | -3,438.451 | -14.724 |
| Inventory
| 7,751.925 | -10,038.122 | -24,041.382 | 0.147 | 0 | 0 | 0 |
| Accounts Payables
| 0 | -316.645 | 1,642.269 | -1,061.974 | 0 | 0 | 93.164 |
| Other Working Capital
| -1,800.787 | -1,950.818 | 3,175.631 | 1,888.039 | -12,619.088 | 10,995.837 | 1,969.6 |
| Other Non Cash Items
| -20,468.106 | -12,824.802 | -4,733.241 | 276.288 | 4,415.375 | 1,677.349 | -1,430.037 |
| Operating Cash Flow
| -48,193.846 | -60,273.986 | -45,907.256 | -15,446.403 | -12,420.889 | 3,775.118 | -1,865.277 |
| Investing Activities: | |||||||
| Investments In Property Plant And Equipment
| -27,991.302 | -65,616.682 | -68,112.635 | -18,111.436 | -18,733.396 | -35,393.304 | -17,206.223 |
| Acquisitions Net
| 0 | 40,038.602 | 26,446.172 | 0 | 0 | 0 | 0 |
| Purchases Of Investments
| 0 | -133,827.1 | -25,239.416 | 0 | 0 | 0 | 0 |
| Sales Maturities Of Investments
| 159,986.542 | -16,121.431 | -26,446.172 | 0 | 0 | 0 | 0 |
| Other Investing Activites
| 469.446 | 26,916.359 | -91,333.199 | -2,800.922 | 694.106 | -2,246.764 | -2,181.864 |
| Investing Cash Flow
| 132,464.686 | -148,610.252 | -184,685.25 | -20,912.358 | -18,039.29 | -37,640.067 | -19,388.087 |
| Financing Activities: | |||||||
| Debt Repayment
| -824.384 | 54,896.395 | -2,914.823 | 2,281.689 | 4,782.68 | 0 | 0 |
| Common Stock Issued
| 1,306.985 | 0 | 0 | 466,093.504 | 0 | 0 | 0 |
| Common Stock Repurchased
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities
| -1,946.993 | -1,671.778 | -1,588.683 | -13,858.64 | 61,358.237 | 39,736.534 | 19,711.868 |
| Financing Cash Flow
| -1,464.392 | 53,183.378 | -4,503.506 | 454,516.553 | 66,140.917 | 39,736.534 | 19,711.868 |
| Other Information: | |||||||
| Effect Of Forex Changes On Cash
| 608.723 | 6,888.277 | -3,176.567 | -277.543 | -72.67 | 236.491 | 0 |
| Net Change In Cash
| 83,581.571 | -148,812.582 | -238,272.579 | 417,880.249 | 35,608.068 | 6,108.076 | -1,541.496 |
| Cash At End Of Period
| 210,483.422 | 125,909.523 | 249,569.236 | 461,375.603 | 45,783.636 | 9,826.473 | 3,718.397 |